List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 389 studies with search of: Tenofovir disoproxil fumarate OR Viread, and"Emtricitabine" [TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
Hide studies with unknown recruitment status.
  Display Options
Rank Status Study
1 Recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/GS-7340;   Drug: elvitegravir/cobicistat/emtricitabine/ tenofovir df
2 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: elvitegravir /emtricitabine /tenofovir DF /GS-9350;   Drug: efavirenz /emtricitabine /tenofovir disoproxil fumarate
3 Recruiting Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
4 Active, not recruiting Study of the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 (QUAD) Versus Atripla(R) in HIV Infected, Antiretroviral Treatment-Naive Adults
Conditions: HIV-1 Infection;   HIV Infections
Interventions: Drug: Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350;   Drug: Atripla
5 Active, not recruiting Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Conditions: HIV;   HIV Infections
Interventions: Drug: GS-9350 + atazanavir + emtricitabine/tenofovir DF;   Drug: Comparator: ritonavir + atazanavir + emtricitabine/tenofovir DF
6 Active, not recruiting Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Condition: HIV Infections
Interventions: Drug: elvitegravir /emtricitabine /tenofovir DF /GS-9350;   Drug: ritonavir and atazanavir and emtricitabine /tenofovir DF
7 Recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: NNRTI plus FTC/TDF
8 Active, not recruiting Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
Condition: HIV-1 Infection
Interventions: Drug: emtricitabine/rilpivirine/tenofovir disoproxil fumarate;   Drug: efavirenz/emtricitabine/tenofovir disoproxil fumarate
9 Active, not recruiting Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Emtricitabine/tenofovir disoproxil fumarate placebo;   Drug: Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate placebo;   Drug: Tenofovir 1% vaginal gel;   Drug: Tenofovir placebo
10 Not yet recruiting Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in Men Who Have Sex With Men
Condition: HIV Infection
Interventions: Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
11 Completed
Has Results 		Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects
Condition: HIV Infections
Interventions: Drug: Emtricitabine (FTC);   Drug: Tenofovir Disoproxil Fumarate (TDF);   Drug: Efavirenz (EFV);   Drug: FTC/TDF;   Drug: FTC/TDF/EFV;   Drug: Lamivudine/zidovudine
12 Active, not recruiting Study to Evaluate Switching From a Regimen Consisting of a Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine/rilpivirine/tenofovir DF tablet
13 Completed Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants
Condition: HIV Infections
Interventions: Drug: Emtricitabine/Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate
14 Active, not recruiting Bone Mineral Density Substudy - An Ancillary Study to MTN-003
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Emtricitabine/tenofovir disoproxil fumarate placebo;   Drug: Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate placebo
15 Completed PK of Tenofovir, Emtricitabine and Efavirenz in Healthy Volunteers
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Atripla®
16 Completed Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients
Condition: HIV Infections
Interventions: Drug: Truvada (tenofovir DF + emtricitabine);   Drug: Emtriva (emtricitabine);   Drug: Viread (tenofovir DF)
17 Active, not recruiting Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: 150 mg tablet GS- 9350;   Drug: ritonavir 100 mg capsule;   Drug: atazanavir 300 mg capsule;   Drug: emtricitabine/tenofovir DF 200/300 mg tablet;   Drug: ritonavir placebo;   Drug: GS-9350 placebo
18 Active, not recruiting Study to Evaluate Switching From Regimens Consisting of Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed Dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Intervention: Drug: emtricitabine /rilpivirine /tenofovir DF tablet
19 Completed Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)
Condition: HIV Infections
Interventions: Drug: Raltegravir;   Drug: Emtricitabine/tenofovir disoproxil fumarate
20 Completed
Has Results 		Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Condition: Human Immunodeficiency Virus Infection
Interventions: Drug: lopinavir/ritonavir (LPV/r);   Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF);   Drug: raltegravir (RAL)

Previous Page Studies Shown (1-20) Next Page (21-40)
† Indicates status has not been verified in more than two years
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services